Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2019 06:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020...
January 24, 2019 07:00 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
December 06, 2018 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings– Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE...
November 08, 2018 16:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
October 31, 2018 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments

Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis...
October 30, 2018 16:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
October 29, 2018 16:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
October 18, 2018 08:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy

Intellia scientists present first robust demonstration of CRISPR-mediated insertion of transgenes in the liver Non-human primate data show high correlation achieved between liver edit and reduction...
September 24, 2018 08:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9...
September 10, 2018 16:30 ET | Source: Intellia Therapeutics, Inc.; CRISPR Therapeutics AG

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr....